Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

KISS1R induces invasiveness of estrogen receptor-negative human mammary epithelial and breast cancer cells.

Endocrinology | 2013

Kisspeptins (KPs), peptide products of the KISS1 metastasis-suppressor gene, are endogenous ligands for a G protein-coupled receptor (KISS1R). KISS1 acts as a metastasis suppressor in numerous human cancers. However, recent studies have demonstrated that an increase in KISS1 and KISS1R expression in patient breast tumors correlates with higher tumor grade and metastatic potential. We have shown that KP-10 stimulates invasion of estrogen receptor α (ERα)-negative MDA-MB-231 breast cancer cells via transactivation of the epidermal growth factor receptor (EGFR). Here, we report that either KP-10 treatment of ERα-negative nonmalignant mammary epithelial MCF10A cells or expression of KISS1R in MCF10A cells induced a mesenchymal phenotype and stimulated invasiveness. Similarly, exogenous expression of KISS1R in ERα-negative SKBR3 breast cancer cells was sufficient to trigger invasion and induced extravasation in vivo. In contrast, KP-10 failed to transactivate EGFR or stimulate invasiveness in the ERα-positive MCF7 and T47D breast cancer cells. This suggested that ERα negatively regulates KISS1R-dependent breast cancer cell migration, invasion, and EGFR transactivation. In support of this, we found that these KP-10-induced effects were ablated upon exogenous expression of ERα in the MDA-MB-231 cells, by down-regulating KISS1R expression. Lastly, we have identified IQGAP1, an actin cytoskeletal binding protein as a novel binding partner of KISS1R, and have shown that KISS1R regulates EGFR transactivation in breast cancer cells in an IQGAP1-dependent manner. Overall, our data strongly suggest that the ERα status of mammary cells dictates whether KISS1R may be a novel clinical target for treating breast cancer metastasis.

Pubmed ID: 23525242 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-EGFR (antibody)

RRID:AB_2096607

This polyclonal targets EGFR

View all literature mentions

GPR54 (N-20) (antibody)

RRID:AB_2131009

This polyclonal targets Human KISS1R

View all literature mentions

Anti-Laminin (antibody)

RRID:AB_2133893

This polyclonal targets LAMA3

View all literature mentions

IQGAP1 (H-109) (antibody)

RRID:AB_2249072

This polyclonal targets IQGAP1

View all literature mentions

Vimentin (R28) Antibody (antibody)

RRID:AB_2288553

This polyclonal targets Vimentin (R28)

View all literature mentions

Purified Mouse Anti-E-cadherin (antibody)

RRID:AB_397580

This monoclonal targets E-cadherin

View all literature mentions

Anti-Phosphotyrosine Antibody, clone PY20 (antibody)

RRID:AB_492625

This monoclonal targets Phosphotyrosine

View all literature mentions